Levothyroxine Sodium generic
levothyroxine sodium is an endocrine system drug owned by Fresenius Kabi Usa. It contains the active ingredient levothyroxine sodium. The drug was first authorised for market use on 24 June, 2011 and is mainly available in powder and intravenous dosage forms. levothyroxine sodium is protected by a total of 6 drug patents, none of which have expired yet.
When will Levothyroxine Sodium generic be available?
The generic version of Levothyroxine Sodium is expected to be released after 01 December, 2036, when the last patent (US10398669 titled 'Levothyroxine liquid formulations') expires. Therefore, it will be quite some time before Levothyroxine Sodium generic becomes available in the market, provided there are no further patent litigations or other market exclusivities awarded that would delay this.
Levothyroxine Sodium uses
levothyroxine sodium is primarily used to treat conditions related to the endocrine system. Its main active ingredient, levothyroxine sodium, is crucial in moderating the body's energy and metabolism. It is commonly prescribed in cases of hypothyroidism to replenish or provide more thyroid hormone, which is normally produced by the thyroid gland.
Levothyroxine Sodium patent expiration
The drug Levothyroxine Sodium currently holds 6 patents. None of these patents have expired, thus inhibiting the release of Levothyroxine Sodium generic. The patent with the latest expiry date is US10398669 with the title 'Levothyroxine liquid formulations'. This patent, along with US9782376 and US11135190, also sharing the same title, expire on 01 December, 2036. Below are the details of the patent: